
Jan 9 (Reuters) - The U.S. Environmental Protection Agency will reassess the safety of herbicide paraquat, its administrator Lee Zeldin said on Friday on X, adding that the body is requiring manufacturers to thoroughly prove that current uses are safe in real-world conditions.
Syngenta, which markets paraquat under the brand name Gramoxone, is among the herbicide's major sellers.
The Swiss-based agricultural chemical company is facing several lawsuits in the U.S., where plaintiffs allege exposure to paraquat caused them to develop Parkinson's, a degenerative brain disease that leads to loss of muscle coordination.
It has previously said there was "no credible evidence" that paraquat causes Parkinson's.
In agricultural settings, paraquat is mostly applied to soybean, corn and cotton crop fields to control invasive weeds and grasses, according to the Environmental Protection Agency.
(Reporting by Costas Pitas and Pooja Menon; Editing by Alan Barona)
LATEST POSTS
- 1
Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines - 2
Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos) - 3
Cygnus XL brings cargo to the ISS for 1st time | Space photo of the day for Dec. 1, 2025 - 4
Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices - 5
UN rights chief says Israeli policy in West Bank 'resembles apartheid system'
The Most Compelling Innovation Developments Somewhat recently
Recalled Super Greens diet supplement powder sickens 45 with salmonella
November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
Far-right AfD invited back to Munich Security Conference in 2026
Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
The gay hockey show no one saw coming — and everyone is suddenly obsessed with
What to know about the hepatitis B shot — and why Trump officials are targeting it













